FIELD: pharmacology.
SUBSTANCE: present invention refers to immunology and biotechnology. There are antibody-antagonist to CD40 with their variable areas derived from an antibody produced of hybridoma 4D11 (FERM BP-7758). The constant areas of antibodies are derived from human IgG4 with mutations S228P and L235E. There are described related coding polynucleotides and the based expression vector. There is disclosed host-cell containing said vector. There is described method for preparing monoclonal antibody and application thereof in the pharmaceutical composition.
EFFECT: application of the invention provides reduced ADCC and CDC activity that can find application in therapy of autoimmune diseases and graft rejection.
10 cl, 26 dwg, 2 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ILT17 ANTIBODY | 2006 |
|
RU2456298C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ILT17 ANTIBODY | 2012 |
|
RU2599450C2 |
| ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY | 2012 |
|
RU2715642C2 |
| HUMANISED AHTH-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES | 2004 |
|
RU2375375C2 |
| HUMANISED ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2006 |
|
RU2407544C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| NOVEL ANTI-HUMAN Igβ ANTIBODY | 2015 |
|
RU2710532C2 |
| ANTI-PSGL-1-ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2650817C2 |
